Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03777982
Title A Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

prostate cancer

Therapies

Abiraterone + Apalutamide + Prednisone

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.